Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(18min)Comments(2)SummaryVoyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease.Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients.Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.Additional upside exists with VY1706 tau-silencing gene therapy and multiple partnered programs, though key risks hinge on upcoming clinical data and regulatory milestones.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thicha Satapitanon/iStock via Getty Images The last time I wrote about Voyager Therapeutics (VYGR), it was with a Seeking Alpha article entitled "Voyager: Anti-Tau Antibody Differentiation For AD Treatment Could Boost Prospects." With respect toThis article was written byTerry Chrisomalis14.82K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.